Abstract
The addition of long-acting beta(2)-adrenoceptor agonist (LABA) therapy to 'low dose' inhaled corticosteroids improves asthma outcomes in terms of lung function, exacerbation rates, and quality of life measures in asthmatic patients who remain symptomatic on low-dose inhaled corticosteroids alone. Such treatment is now included in guidelines of asthma therapy on the basis of class A evidence from large placebo-controlled trials. Data on the cost-benefit of such treatment is less compelling, but suggests that for patients with mild asthma this clinical improvement is gained at the expense of an increase in direct costs (mostly drug costs), whereas for patients with more severe asthma there may be a cost benefit, largely from reduced costs of exacerbations. Recently, combination inhalers containing both LABA and corticosteroid in the same device have been introduced. Although it is said that a single inhaler (with some immediate symptom relief) may aid patient adherence, there are no firm data to support this, nor are there any cost-effectiveness data on this point. Overall, these devices have been priced at less than the two drugs given separately, but prospective studies evaluating costs in clinical settings are required.
References
Mar 26, 1992·The New England Journal of Medicine·K B WeissT A Hodgson
Feb 1, 1992·Thorax·E F JuniperT K Hiller
Jun 15, 1992·The Medical Journal of Australia·A BaumanS R Leeder
Jul 23, 1994·Lancet·A P GreeningG Shaw
Apr 1, 1994·International Journal of Epidemiology·M L BurrF Nagel
May 1, 1996·American Journal of Respiratory and Critical Care Medicine·A WoolcockL A Jacques
Apr 1, 1996·The European Respiratory Journal·P J BarnesJ B Klim
Oct 6, 1997·American Journal of Respiratory and Critical Care Medicine·D H SmithW B Saunders
Nov 14, 1997·The New England Journal of Medicine·R A PauwelsA Ullman
Feb 1, 2000·Respiratory Medicine·M AubierK O Steinmetz
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·G ShapiroT Shah
Jun 16, 2000·The Journal of Allergy and Clinical Immunology·M KavuruT Shah
Aug 5, 2000·Respiratory Medicine·C JenkinsM H James
Aug 5, 2000·Respiratory Medicine·B LundbäckR M Thwaites
Dec 12, 2000·The Journal of Allergy and Clinical Immunology·H S NelsonK Knobil
Dec 29, 2000·Drugs·A Markham, B Jarvis
Jun 26, 2001·Respiratory Medicine·F AnderssonUNKNOWN Formoterol and Corticosteroid Establishing Therapy. International Study Group
Feb 15, 2002·The European Respiratory Journal·P J Barnes